Shanghai, China – December 15, 2025

中国上海——2025年12月15日

–

–

MicroPort Scientific Corporation

微创医疗科学公司

(00853.HK, “

(00853.HK, “

MicroPort

微创

®

®

”) today announced that the strategic merger between its subsidiaries MicroPort CardioFlow Medtech Corporation (02160.HK, 'MicroPort

“）今天宣布其子公司微创心通医疗科技有限公司（02160.HK，'微创心通'）之间的战略合并。

®

®

CardioFlow') and MicroPort

心血管流量') 和微创科技

®

®

Cardiac Rhythm Management ('MicroPort

心脏节律管理（‘微创’

®

®

CRM') has been approved by MicroPort

CRM已获微创®批准

®

®

CardioFlow’s shareholders. MicroPort

CardioFlow的股东。微创医疗

®

®

CardioFlow will acquire MicroPort

CardioFlow将收购MicroPort

®

®

CRM through a non-cash transaction, issuing new shares with a total consideration of USD 680 million.

通过非现金交易的CRM，发行新股，总对价为6.8亿美元。

The merger aims to integrate core strengths across structural heart intervention and cardiac rhythm management. It seeks to address the complex diagnostic and treatment needs covering all causes and stages of heart failure, and to develop a global, specialized device platform for heart failure that spans the entire process of monitoring, diagnosis, treatment, and management..

该合并旨在整合结构性心脏介入和心脏节律管理的核心优势，致力于满足覆盖心衰所有病因和阶段的复杂诊断和治疗需求，并打造一个贯穿心衰监测、诊断、治疗和管理全过程的全球专业化器械平台。

Currently, the company has a rich pipeline in development covering the full cycle of heart failure management. The first heart failure product post-merger - IABP (Intra-Aortic Balloon Pump) - is expected to be approved in China in 2026.

目前，该公司在研产品线丰富，覆盖心力衰竭管理的全周期。预计合并后的首款心衰产品——IABP（主动脉内球囊泵）将于2026年在中国获批。

Heart failure is not a single disease, but rather a complex clinical syndrome resulting from various factors that cause structural and/or functional abnormalities of the heart, impairing ventricular systolic and/or diastolic function. It encompasses four stages: the pre‑heart failure risk stage, early heart failure, symptomatic heart failure, and end‑stage heart failure.

心力衰竭不是单一的疾病，而是一种复杂的临床综合征，由各种因素引起心脏结构和/或功能异常，导致心室收缩和/或舒张功能受损。它包括四个阶段：心衰前期风险阶段、早期心衰、症状性心衰和终末期心衰。

Globally, over 64 million people are affected by heart failure.

全球有超过 6400 万人受到心力衰竭的影响。

1

1

. However, despite the large patient base and complex etiological landscape, device-based therapies in heart failure remains relatively limited. Current device applications are predominantly concentrated in patients with end-stage heart failure, while there is insufficient coverage in key areas such as prevention, assessment, and monitoring for the larger proportion of patients in the early and intermediate stages..

然而，尽管患者群体庞大且病因复杂，心力衰竭的器械治疗仍然相对有限。目前器械应用主要集中于终末期心力衰竭患者，而在预防、评估和监测等关键领域，对早期和中期较大比例患者的覆盖仍然不足。

Through this integration, MicroPort

通过此次整合，微创

®

®

will make a strategic entry into heart failure, one of the highest-potential value segments within the cardiovascular disease landscape. By combining MicroPort

将战略性地进军心力衰竭领域，这是心血管疾病领域中最具潜力的高价值细分市场之一。通过结合微创

®

®

CRM’s strengths in AI-enabled diagnostics and algorithm development with MicroPort

微创医疗在人工智能诊断和算法开发方面的CRM优势

®

®

CardioFlow’s deep expertise in structural heart interventions, precision delivery systems, biomaterials and hemodynamic platforms, the company possesses not only technological reserves but also capabilities that have been validated through long-term market and clinical practice. This provides solid support for building a comprehensive device-based diagnosis and treatment system for heart failure, one that addresses all etiologies, covers all stages of the disease course, and spans the entire process of monitoring, diagnosis, treatment, and management..

CardioFlow公司在结构性心脏病介入、精密输送系统、生物材料和血液动力学平台方面拥有深厚的专业知识，公司不仅具备技术储备，而且其能力已经过长期市场和临床实践的验证。这为构建一个基于器械的心力衰竭综合诊治体系提供了坚实的支持，该体系涵盖所有病因、覆盖疾病全程的各个阶段，并贯穿监测、诊断、治疗和管理的整个过程。

At the same time, the strategic merger represents a key step in MicroPort

同时，这一战略性合并代表着微创的一个关键步骤

®

®

’s efforts to optimize resource allocation and enhance its overall competitiveness. It provides a solid foundation for cultivating a world-leading cardiovascular platform and injects strong momentum into the company’s long-term, high-quality growth, as reflected in the following aspects:

优化资源配置，提升整体竞争力。为打造世界级的心血管平台提供了坚实基础，也为公司长期高质量增长注入了强劲动力，具体表现在以下几个方面：

Portfolio Integration and Global Expansion

投资组合整合与全球扩张

: Product pipeline integration will enable a more comprehensive and rich product portfolio across structural heart disease and cardiac rhythm management, supporting broader hospital coverage and accelerating global market penetration through MicroPort

产品管线整合将使结构性心脏病和心脏节律管理领域的产品组合更加全面和丰富，支持更广泛的医院覆盖，并通过微创加速全球市场渗透。

®

®

CRM's mature sales channels.

CRM的成熟销售渠道。

Global Resource Alignment and Operational Synergies:

全球资源调整与运营协同：

The merger strengthens global collaboration across sales, distribution, and operational infrastructure. Leveraging MicroPort

此次合并加强了销售、分销和运营基础设施方面的全球合作。利用微创医疗

®

®

CRM's established operational teams and infrastructure is expected to improve localized operations in clinical development, quality systems, and customer support.

CRM建立的运营团队和基础设施预计将改善临床开发、质量体系和客户支持方面的本地化运营。

R&D Collaboration and Supply Chain Integration:

研发合作与供应链整合：

Combined R&D capabilities will support deeper technology integration and innovation. Supply chain integration will enhance economies of scale, strengthen resilience, and mitigate sourcing risks through diversified manufacturing and supplier networks.

整合的研发能力将支持更深层次的技术融合与创新。供应链的整合将增强规模经济，加强弹性，并通过多样化的制造和供应商网络来降低采购风险。

Looking ahead, the combined company will prioritize end-to-end comprehensive heart failure care as a core strategic focus and aims to build a globally leading platform capable of delivering end-to-end, integrated solutions across the full care continuum. This strategy will provide sustained momentum for MicroPort®’s long-term advancement in major disease areas..

展望未来，合并后公司将以心衰全疗程管理为核心战略重点之一，致力于打造全球领先的心衰全病程平台，提供覆盖全疗程的端到端综合解决方案。该战略将为微创®在重大疾病领域的长远发展提供持续动力。

This initiative represents not only a significant milestone in MicroPort®’s heart failure journey, but also a concrete step in fulfilling the company’s purpose of “

这一举措不仅代表了微创®心衰旅程中的重要里程碑，也是实现公司“

Pushing boundaries so that patients everywhere can enjoy better and longer lives

推动界限，让世界各地的患者都能享有更好、更长的生命。

” by

“由

providing trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives

提供对延长和重塑所有生命的一流解决方案的可靠且普遍的访问途径

.

。

Shahim, Bahira, et al. “Global Public Health Burden of Heart Failure: An Updated Review.”

沙希姆，巴希拉，等。《心力衰竭的全球公共卫生负担：最新综述》。

Cardiac Failure Review

心力衰竭评论

, vol. 9, e11, 2023, doi:10.15420/cfr.2023.05.

，第9卷，e11，2023年，doi:10.15420/cfr.2023.05。

About MicroPort

关于微创

®

®

Since 1998, MicroPort

自 1998 年以来，微创

®

®

(MicroPort Scientific Corporation; HKEX: 00853) has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can live better and longer lives. As a global medical device company, MicroPort

微创医疗科技集团（HKEX: 00853）不断突破障碍，加速获取改变生命的解决方案，使世界各地的患者能够过上更好、更长寿的生活。作为一家全球性的医疗设备公司，微创医疗科技集团

®

®

provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, endovascular, neurovascular and surgical robotics. Serving over 100 countries and 20,000 hospitals, MicroPort

提供覆盖十二个治疗领域的解决方案，包括心血管、骨科、血管内、神经血管和手术机器人。服务超过100个国家和20,000家医院，微创...

®

®

provides a medical solution to a patient every 5 seconds.

每5秒为患者提供一个医疗解决方案。

More information is available at

更多信息请访问

www.microport.com

www.microport.com

.

。

About MicroPort

关于微创

®

®

CardioFlow

心血管流量

MicroPort

微创

®

®

CardioFlow is an innovation leader in the global structural heart disease interventional treatment field. It holds a leading position in the Chinese transcatheter aortic valve implantation (TAVI) market and has officially entered a new phase of scaled global operations and high-quality development.

心通医疗是全球结构性心脏病介入治疗领域的创新领导者，其在中国经导管主动脉瓣植入术（TAVI）市场占据领先地位，并正式迈入规模化全球运营与高质量发展的新阶段。

Through independent R&D and collaborative development with global partners, MicroPort.

通过自主研发和与全球合作伙伴共同开发，微创。

®

®

CardioFlow has built a forward-looking innovative pipeline covering transcatheter solutions for aortic, mitral, and tricuspid valve diseases, interventional treatment for post-myocardial infarction ventricular septal defects, and stroke prevention related to atrial fibrillation, continuously leading industry technological innovation and global market expansion..

心通医疗已建立具有前瞻性及创新性的在研产品组合，覆盖主动脉瓣、二尖瓣及三尖瓣疾病的经导管解决方案、心肌梗塞后室间隔缺损的介入治疗以及与房颤相关的卒中预防等领域，持续引领行业技术创新及全球市场拓展。

More information is available at:

更多信息请访问：

https://en.cardioflowmedtech.com/

https://zh.cardioflowmedtech.com/

About MicroPort

关于微创

®

®

CRM:

客户关系管理：

MicroPort

微创

®

®

CRM is a global leader in the field of cardiac rhythm management, headquartered in Clamart, near Paris, France. With more than 60 years of expertise and continuous innovation, MicroPort

CRM是心脏节律管理领域的全球领导者，总部位于法国巴黎附近的克拉马。拥有超过60年的专业经验并不断创新，微创®...

®

®

CRM currently boasts 12 pipelines and over 40 marketed products across core cardiac rhythm management segments, including pacemakers, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) systems, and Holter ECG diagnostic solutions.

CRM目前在核心心脏节律管理领域拥有12条产品线和40多种上市产品，涵盖起搏器、植入式心律转复除颤器（ICD）、心脏再同步治疗（CRT）系统以及Holter心电图诊断解决方案。

More information is available at

更多信息请访问

www.microport.com

www.microport.com

.

。